2024年欧洲肿瘤内科学会乳腺癌年会研究进展  

Advancements in breast cancer research: insights from the European Society for Medical Oncology Breast Cancer Congress 2024

作　　者：吕文杰[1] 吴萍[1] Wenjie Lv;Ping Wu(Department of Breast Surgery,Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200092,China)

机构地区：[1]上海交通大学医学院附属新华医院乳腺外科,上海市200092

出　　处：《中国肿瘤临床》2024年第11期572-579,共8页Chinese Journal of Clinical Oncology

摘　　要：2024年5月举行的欧洲肿瘤内科学会乳腺癌年会(European Society for Medical Oncology Breast Cance,ESMO BC)在德国柏林召开。本次年会展示了一系列针对乳腺癌治疗的最新进展,包括创新疗法和诊治策略。特别值得关注的是,细胞周期蛋白依赖性激酶4和6(cyclin-dependent kinases 4 and 6,CDK4/6)抑制剂联合内分泌治疗(endocrine therapy,ET)在早期乳腺癌新辅助治疗中的研究尚未达到主要终点,而探索性分析结果表明,该领域仍有待进一步研究。CDK4/6抑制剂联合ET继续作为高危患者辅助治疗的标准。同时,阿贝西利在携带BRCA1/2突变的患者亚组中显示出初步的一致性获益。瑞波西利虽然不良反应可控,但仍需进行密切监测。新型CDK4选择性抑制剂、AKT抑制剂、抗体药物偶联物(antibody-drug conjugates,ADC)以及免疫治疗为晚期乳腺癌患者提供了新的治疗选项。本次年会所展现的研究成果,不仅代表了乳腺癌治疗领域的进步,也为未来的研究方向和患者治疗策略提供了新的视野。本文就此次年会上重点的研究进展进行综述。Berlin became the focal point for innovation in breast cancer treatment at the European Society for Medical Oncology Breast Cancer(ESMO BC)Annual Meeting held in May 2024.The conference showcased the latest advancements in breast cancer treatment,including innovative therapies and strategies.Notably,research on cyclin-dependent kinase 4 and 6(CDK4/6)inhibitors combined with endocrine therapy(ET)in the neoadjuvant treatment of early breast cancer,though not yet reaching its primary endpoint,suggests further research is needed in this area.The combination of CDK4/6 inhibitors with ET continues to be the standard adjuvant therapy for high-risk patients,with abemaciclib showing consistent preliminary benefits in a subgroup of patients with germline BRCA1/2 mutations.Although ribociclib’s adverse reactions can be managed,its use requires close monitoring.New selective CDK4 inhibitors,AKT inhibitors,antibody-drug conjugates,and immunotherapies offer additional treatment alternatives for patients with advanced breast cancer.This year's meeting showcased advancements in breast cancer treatment and provides new perspectives for future research directions and patient treatment strategies.This article overviews the critical research developments presented at the meeting.

关 键 词：乳腺癌 研究进展 免疫治疗 CDK4/6抑制剂 抗体药物偶联物 

分 类 号：R737.9[医药卫生—肿瘤]